导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.11% | 1944/4773 |
| 近一周 | -1.82% | 761/5462 |
| 近一月 | -4.63% | 2604/5421 |
| 近一季 | -5.21% | 1790/5209 |
| 近半年 | -7.26% | 3193/4920 |
| 近一年 | 7.49% | 1298/4366 |
| 近两年 | 71.85% | 944/2954 |
| 近三年 | 40.24% | 718/2253 |
| 成立以来 | 63.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.84% 1433/4961 |
9.03% 2509/5312 |
- - |
- - |
| 2025 | 34.77% 1021/4813 |
3.80% 1039/3635 |
1.78% 2148/4076 |
24.84% 1430/4524 |
2.18% 1057/4813 |
| 2024 | 7.93% 1604/3463 |
-0.77% 1143/2808 |
-3.97% 1445/3014 |
12.15% 2403/3129 |
0.99% 1143/3463 |
| 2023 | -2.13% 557/2656 |
8.12% 493/2280 |
-2.93% 716/2385 |
-2.65% 711/2515 |
-4.21% 913/2655 |
| 2022 | -16.55% 492/2207 |
-10.04% 375/1919 |
4.50% 1008/2016 |
-11.60% 551/2113 |
0.42% 1495/2208 |
| 2021 | -0.81% 762/1822 |
-1.15% 440/1255 |
10.42% 463/1330 |
0.08% 471/1466 |
-9.20% 1596/1822 |
| 2020 | 20.65% 713/1250 |
-4.70% 380/1028 |
19.24% 307/1067 |
5.60% 906/1164 |
0.54% 1056/1184 |
| 2019 | 27.47% 544/1092 |
19.51% 626/739 |
4.61% 22/788 |
-2.32% 694/850 |
4.38% 803/918 |
| 2018 | -20.85% 201/834 |
- - |
-10.12% 302/631 |
-4.91% 353/660 |
-7.77% 71/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证500指数增强C VS. 长安沪深300非周期A(740101) |